Peregrine Capital Management LLC Has $12.55 Million Stock Holdings in Artivion, Inc. $AORT

Peregrine Capital Management LLC boosted its position in Artivion, Inc. (NYSE:AORT) by 15.9% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 342,795 shares of the company’s stock after buying an additional 47,074 shares during the period. Peregrine Capital Management LLC owned approximately 0.71% of Artivion worth $12,553,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Aster Capital Management DIFC Ltd grew its stake in Artivion by 402.3% in the third quarter. Aster Capital Management DIFC Ltd now owns 648 shares of the company’s stock valued at $27,000 after acquiring an additional 519 shares during the period. Caitong International Asset Management Co. Ltd acquired a new position in shares of Artivion during the third quarter worth approximately $27,000. Rockefeller Capital Management L.P. raised its position in shares of Artivion by 150.0% during the fourth quarter. Rockefeller Capital Management L.P. now owns 665 shares of the company’s stock worth $30,000 after purchasing an additional 399 shares during the period. Larson Financial Group LLC lifted its holdings in shares of Artivion by 148.5% in the 4th quarter. Larson Financial Group LLC now owns 942 shares of the company’s stock worth $43,000 after purchasing an additional 563 shares in the last quarter. Finally, USA Financial Formulas lifted its holdings in shares of Artivion by 163.5% in the 4th quarter. USA Financial Formulas now owns 1,133 shares of the company’s stock worth $52,000 after purchasing an additional 703 shares in the last quarter. 86.37% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, SVP Andrew M. Green sold 44,001 shares of the stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $20.70, for a total value of $910,820.70. Following the completion of the sale, the senior vice president owned 60,259 shares in the company, valued at $1,247,361.30. This represents a 42.20% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.30% of the stock is currently owned by insiders.

Artivion Trading Up 0.6%

Shares of Artivion stock opened at $22.53 on Wednesday. The company has a market capitalization of $1.09 billion, a P/E ratio of 93.88 and a beta of 1.26. The stock has a fifty day simple moving average of $25.41 and a 200 day simple moving average of $34.97. Artivion, Inc. has a 12-month low of $19.16 and a 12-month high of $48.25. The company has a current ratio of 3.86, a quick ratio of 2.80 and a debt-to-equity ratio of 0.48.

Analyst Upgrades and Downgrades

A number of brokerages have commented on AORT. Wall Street Zen lowered shares of Artivion from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Citizens Jmp reduced their price objective on shares of Artivion from $53.00 to $48.00 and set a “market outperform” rating for the company in a report on Friday, May 8th. Needham & Company LLC reduced their price objective on shares of Artivion from $58.00 to $44.00 and set a “buy” rating for the company in a report on Friday, May 8th. Weiss Ratings downgraded shares of Artivion from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, June 8th. Finally, Stifel Nicolaus set a $45.00 target price on shares of Artivion in a report on Monday, June 1st. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $44.17.

Artivion Profile

Artivion, Inc (NYSE: AORT) is a global medical technology company that develops, manufactures and markets implantable tissue products and surgical devices for cardiac and vascular surgery. The company’s portfolio includes biologic implants derived from human and animal tissue, such as allografts and xenografts, as well as synthetic scaffolds and surgical adhesives. These products are designed to repair, reinforce or replace damaged cardiovascular and thoracic tissues during procedures such as aortic repair, heart valve surgery and vascular reconstruction.

Originally founded in 1984 under the name CryoLife, the company rebranded as Artivion in early 2022 to reflect its broader mission in cardiovascular innovation.